Cantor Fitzgerald Initiates Coverage on Athira Pharma (NASDAQ:LONA)

Equities researchers at Cantor Fitzgerald assumed coverage on shares of Athira Pharma (NASDAQ:LONA) in a report released on Thursday. The brokerage set an “overweight” rating on the stock.

Several other brokerages have also recently issued reports on LONA. Wall Street Zen upgraded Athira Pharma to a “hold” rating in a research note on Saturday, February 14th. Mizuho upgraded Athira Pharma from a “neutral” rating to an “outperform” rating and set a $10.00 price objective for the company in a research report on Thursday, February 19th. Finally, Weiss Ratings began coverage on Athira Pharma in a research note on Wednesday, February 11th. They issued a “sell (d-)” rating on the stock. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Athira Pharma presently has a consensus rating of “Hold” and an average target price of $10.00.

Athira Pharma Stock Performance

Shares of NASDAQ:LONA opened at $5.81 on Thursday. Athira Pharma has a one year low of $2.20 and a one year high of $8.36.

Athira Pharma Company Profile

Athira Pharma, traded as LONA on the NASDAQ, is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapeutics intended to restore neuronal health and function in neurodegenerative and cognitive disorders. The company’s research approach centers on modulating pathways involved in synaptic repair and neurotrophic signaling to address underlying neuronal dysfunction rather than solely treating symptoms.

Athira’s lead investigational therapy is fosgonimeton (ATH-1017), a small-molecule candidate designed to potentiate hepatocyte growth factor (HGF)/MET pathway signaling with the aim of improving synaptic connectivity and cognitive performance in patients with conditions such as Alzheimer’s disease and related cognitive impairments.